Furue Masutaka, Chiba Takahito, Takeuchi Satoshi
Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
Asia Pac Allergy. 2011 Jul;1(2):64-72. doi: 10.5415/apallergy.2011.1.2.64. Epub 2011 Jul 28.
Atopic dermatitis (AD) is a common, chronic or chronically relapsing, severely pruritic, eczematous skin disease. AD is the second most frequently observed skin disease in dermatology clinics in Japan. Prevalence of childhood AD is 12-13% in mainland Japan; however, it is only half that (about 6%) in children from Ishigaki Island, Okinawa. Topical steroids and tacrolimus are the mainstay of treatment. However, the adverse effects and emotional fear of long-term use of topical steroids have induced a "topical steroid phobia" in patients throughout the world. Undertreatment can exacerbate facial/periocular lesions and lead to the development of atopic cataract and retinal detachment due to repeated scratching/rubbing/patting. Overcoming topical steroid phobia is a key issue for the successful treatment of AD through education, understanding and cooperation of patients and their guardians.
特应性皮炎(AD)是一种常见的、慢性或慢性复发性、严重瘙痒的湿疹性皮肤病。AD是日本皮肤科诊所中第二常见的皮肤病。日本本土儿童AD的患病率为12%-13%;然而,冲绳石垣岛儿童的患病率仅为其一半(约6%)。外用糖皮质激素和他克莫司是主要治疗药物。然而,长期使用外用糖皮质激素的不良反应和情感恐惧在全球患者中引发了“外用糖皮质激素恐惧症”。治疗不足会加重面部/眼周病变,并因反复搔抓/摩擦/拍打导致特应性白内障和视网膜脱离的发生。通过患者及其监护人的教育、理解与合作克服外用糖皮质激素恐惧症是成功治疗AD的关键问题。